Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers December 19, 2018
Pharmacy Choice - Pharmaceutical News - Arrevus announces three new appointments to the company's Board Of Directors - December 19, 2018

Pharmacy News Article

 3/13/18 - Arrevus announces three new appointments to the company's Board Of Directors

RALEIGH, N.C., March 13, 2018 /PRNewswire/ Arrevus Inc., a biotechnology company developing chaperone protein inhibitors to combat antimicrobial resistance, announced the addition of three new board members: Barry Garfinkle, Joe McMahon, and Joe St. Geme. "We feel privileged to have the depth of experience and guidance available to us with the appointments of each of our new Board members. Arrevus is well-poised to continue developing novel solutions to the growing threat of antibiotic-resistant infections," said Carl N. Kraus, M.D., President and CEO of Arrevus.

Barry D. Garfinkle, Ph.D., is the Principal of Garfinkle & Associates Consulting. Formerly the Vice President of Biological Sciences and Strategy at Merck, Dr. Garfinkle has served on the USP Council of Experts, first on the Microbiology Committee and then as Chair of the Vaccine and Virology Committee. Dr. Garfinkle has also provided training to the U.S. FDA in microbiology and was a member of the Pharmaceutical Manufacturers Association.

Joe McMahon is currently CEO of Bioventure Partners, providing growth advisory services and investments to high-impact, technology-driven companies in the life science and medical device sectors. Mr. McMahon was the former President and CEO of both KBI Biopharma and kSep Systems. KBI is a global contract development and manufacturing organization serving the biopharmaceutical industry and was acquired by JSR Corporation in 2015. kSep Systems, a spin-out of KBI Biopharma, was acquired by Sartorius, AG in 2016.

Joe St. Geme, M.D., is the Physician-in-Chief and Chairman of the Department of Pediatrics at Children's Hospital of Philadelphia and Chairman of the Department of Pediatrics at the University of Pennsylvania. He is a Professor of Pediatrics and Microbiology and a member of the Microbiology, Virology, and Parasitology Program at the University of Pennsylvania. He previously served as the Director of Pediatric Infectious Diseases at Washington University in St. Louis, MO. Dr. St. Geme's laboratory is focusing on bacterial pathogenesis and characterizing common protein secretion pathways as targets for new antimicrobials with activity against pathogenic gram-negative bacteria.

About Arrevus

Arrevus is a biotechnology company whose mission is to eliminate the threat of antibiotic resistance and improve treatment outcomes for serious infectious diseases. Arrevus is applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs). Arrevus has its headquarters in Raleigh, NC. For more information about Arrevus Inc., visit or email

Cision View original content with multimedia:

SOURCE Arrevus

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Dec 19: Efficacy vs. Safety: Treating BPH & Incontinence in the Elderly
Last Chance
Dec 20: Adult Immunizations: A Guide for Pharmacists, Techs & NPs
Dec 27: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Jan 02: School is Out! Life is in Session: The Importance of Professional Development in Pharmacy
Jan 03: Management of Bipolar Disorder
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement